Phase 2 COPD Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older who have voluntarily agreed to participate by signing a consent form
• People who have previously received a stem cell transplant from a donor (using bone marrow, blood stem cells, or umbilical cord blood), using any of the standard transplant preparation methods
• People whose transplant has successfully taken hold, shown by blood count levels meeting specific thresholds, without needing growth factor support or blood transfusions in the 7 days before screening
• People who have been diagnosed with moderate-to-severe chronic graft-versus-host disease (a condition where donor cells affect the recipient's body) based on 2014 NIH guidelines
• People who have already tried 2 to 5 previous systemic treatments for their chronic graft-versus-host disease but still have active disease
• People with a general health/activity score of 0–2 on a standard medical scale (meaning able to carry out daily activities with at most some limitations)
• People who are able to swallow tablets
• People who are taking certain other immune-suppressing medications that do not interact with the trial drug

Who may not be able to join:

• People whose original cancer or blood disease has come back, or whose transplanted cells have not fully taken over from their own
• People currently using other medications in a similar drug class (JAK inhibitors), mesenchymal stem cells, or a drug called belumosudil — though people who stopped these treatments more than 8 weeks ago, or who stopped JAK inhibitors due to side effects, may still be considered (confirm with trial site)
• People with severe lung involvement from their graft-versus-host disease, based on specific breathing test results or symptom scores
• People who have developed a condition called post-transplant lymphoproliferative disease (an abnormal growth of immune cells after transplant)
• People with certain significant health abnormalities, including poorly controlled high blood pressure despite medication, or liver or kidney function levels outside acceptable ranges on blood tests
• People who have had a major heart event (such as a heart attack or stroke) within the past 6 months
• People who have a heart rhythm problem that requires treatment at the time of screening
• People with digestive system conditions that could prevent the body from properly absorbing the trial medication
• People who had surgery within 4 weeks before screening and have not fully recovered
• People with an active or uncontrolled infection (bacterial, viral, fungal, or parasitic) that currently requires treatment
• People with active tuberculosis within the past 6 months
• People with epilepsy, or who are taking medications that affect mood, mental state, or cause sedation
• People who are pregnant, breastfeeding, or unwilling to use contraception during the trial and for 4 weeks after it ends
• People who have had a cancer diagnosis within the past 5 years, other than the condition that led to their transplant
• People currently taking blood-thinning or anti-clotting medications, with the exception of a specific type of heparin (low-molecular-weight heparin)
• People who have used herbal medicines within 1 week before enrolling
• People known to have an allergy or sensitivity to the trial drug or any of its ingredients
• People who have participated in another clinical trial within the past 4 weeks, or within a longer period based on the previous trial drug (whichever is longer)
• People considered unsuitable for the trial by the medical team running the study

Important: Always verify eligibility with the trial site directly before applying.